Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
ACET Stock Summary
Top 10 Correlated ETFs
ACET
In the News
The Penny Stock A-List: 7 High-Profile Companies on the Verge of Greatness
In most cases, investors should stay away from penny stocks. They're wild, they're unpredictable and they tend to lose their stakeholders money more so than they return.
Adicet Bio (ACET) Loses -16.39% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
The heavy selling pressure might have exhausted for Adicet Bio (ACET) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
ACET Stock Earnings: Adicet Bio Meets EPS for Q4 2023
Adicet Bio (NASDAQ: ACET ) just reported results for the fourth quarter of 2023. Adicet Bio reported earnings per share of -69 cents.
Are Medical Stocks Lagging Adicet Bio (ACET) This Year?
Here is how Adicet Bio, Inc. (ACET) and Adma Biologics (ADMA) have performed compared to their sector so far this year.
Adicet Bio to Participate in a Fireside Chat at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference
REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President and Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference being held March 26, 2024. Details of the event are as follows: Date: Tuesday, March 26, 2024 Time: 10.
3 High-Risk Stocks That Could Pay Off in the Millions
High-risk stocks could potentially turn the tables for investors willing to stomach the risk. Moreover, as the Nasdaq Composite hit a fresh high last Friday, ahead of its 2021 peak, the market's appetite for risk continues to grow.
Is Adicet Bio (ACET) Stock Outpacing Its Medical Peers This Year?
Here is how Adicet Bio, Inc. (ACET) and Adma Biologics (ADMA) have performed compared to their sector so far this year.
7 Top-Tier Penny Stocks for a Smart Bet
Penny stocks are heating up as the S&P 500 hits new highs, signaling opportunity. With the S&P 500 posting new highs multiple times in the past few months and prospects of lower interest rates, the stage is set for potentially lucrative penny stock investments.
7 Biotech Penny Stocks on the Verge of Clinical Trial Victory
While targeting the therapeutic side of the healthcare sector can be quite lucrative, nothing matches the excitement of biotech penny stocks. Of course, the excitement goes toward both extremes of the emotional spectrum.
Is Adicet Bio (ACET) Outperforming Other Medical Stocks This Year?
Here is how Adicet Bio, Inc. (ACET) and Adma Biologics (ADMA) have performed compared to their sector so far this year.
ACET Financial details
ACET Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0.42 | 0.05 | 2.45 | 0.31 | 0.61 | |
Net income per share | -0.47 | -1.44 | -5.01 | -2 | -1.63 | |
Operating cash flow per share | -0.93 | -1.42 | -5.68 | -1.65 | -1.09 | |
Free cash flow per share | -0.97 | -1.48 | -5.81 | -2.07 | -1.5 | |
Cash per share | 5.51 | 3.19 | 12.93 | 8.97 | 6.27 | |
Book value per share | 5.32 | -3.08 | -14.53 | -5.44 | -5.8 | |
Tangible book value per share | 5.32 | -3.08 | 12.1 | 9.16 | 6.64 | |
Share holders equity per share | 5.32 | -3.08 | -14.53 | -5.44 | -5.8 | |
Interest debt per share | 0 | 0 | 2.97 | 0.68 | 0.51 | |
Market cap | 1.18B | 204.32M | 102.85M | 541.35M | 367.26M | |
Enterprise value | 1.17B | 193.71M | 40.15M | 284.75M | 130.62M | |
P/E ratio | -127.11 | -7.26 | -2.8 | -8.73 | -5.48 | |
Price to sales ratio | 144.49 | 205.35 | 5.74 | 55.64 | 14.7 | |
POCF ratio | -65.02 | -7.33 | -2.48 | -10.6 | -8.2 | |
PFCF ratio | -62.03 | -7.06 | -2.42 | -8.45 | -5.97 | |
P/B Ratio | 11.34 | -3.38 | -0.97 | -3.22 | -1.54 | |
PTB ratio | 11.34 | -3.38 | -0.97 | -3.22 | -1.54 | |
EV to sales | 143.63 | 194.69 | 2.24 | 29.27 | 5.23 | |
Enterprise value over EBITDA | -135.59 | -7.21 | -1.02 | -4.6 | -1.87 | |
EV to operating cash flow | -64.63 | -6.95 | -0.97 | -5.58 | -2.92 | |
EV to free cash flow | -61.66 | -6.69 | -0.94 | -4.44 | -2.12 | |
Earnings yield | -0.01 | -0.14 | -0.36 | -0.11 | -0.18 | |
Free cash flow yield | -0.02 | -0.14 | -0.41 | -0.12 | -0.17 | |
Debt to equity | 0 | 0 | -0.2 | -0.12 | -0.09 | |
Debt to assets | 0 | 0 | 0.14 | 0.06 | 0.06 | |
Net debt to EBITDA | 0.81 | 0.39 | 1.59 | 4.14 | 3.39 | |
Current ratio | 19.16 | 4.32 | 6.77 | 17.31 | 13.25 | |
Interest coverage | 0 | 0 | -292.47 | -349.05 | -906.89 | |
Income quality | 1.96 | 0.99 | 1.13 | 0.82 | 0.64 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 1.03 | 8.74 | 1.27 | 2.28 | 1.05 | |
Research and developement to revenue | 1.8 | 23.81 | 1.92 | 5.03 | 2.85 | |
Intangibles to total assets | 0 | 0 | 0.14 | 0.06 | 0.06 | |
Capex to operating cash flow | 0.05 | 0.04 | 0.02 | 0.26 | 0.37 | |
Capex to revenue | -0.11 | -1.08 | -0.06 | -1.34 | -0.67 | |
Capex to depreciation | -0.72 | -0.86 | -0.81 | -8.48 | -6.52 | |
Stock based compensation to revenue | 0.3 | 1.18 | 0.29 | 1.29 | 0.69 | |
Graham number | 7.54 | 9.98 | 40.47 | 15.66 | 14.59 | |
ROIC | -0.14 | 0.52 | 0.58 | 0.48 | 0.36 | |
Return on tangible assets | -0.08 | -0.34 | -0.28 | -0.19 | -0.22 | |
Graham Net | 5.22 | -4.01 | 6.98 | 7.89 | 5.38 | |
Working capital | 103.82M | 49.32M | 80.63M | 266.12M | 241.33M | |
Tangible asset value | 104.2M | -60.37M | 88.55M | 283.67M | 272.88M | |
Net current asset value | 103.8M | -77.77M | 50.61M | 246.63M | 222.69M | |
Invested capital | 0 | 0 | -0.2 | -0.12 | -0.09 | |
Average receivables | 130.44M | 467.5K | 1.83M | 1.47M | 324.5K | |
Average payables | 45.01M | 526K | 1.3M | 2.41M | 3.83M | |
Average inventory | 68.19M | 336K | -1.21M | 792K | 3.62M | |
Days sales outstanding | 0 | 342.99 | 55.68 | 8.03 | 6.35 | |
Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 0 | 1.06 | 6.56 | 45.47 | 57.45 | |
Payables turnover | 0 | 0 | 0 | 0 | 0 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | -0.09 | 0.47 | 0.34 | 0.37 | 0.28 | |
Capex per share | -0.04 | -0.05 | -0.14 | -0.42 | -0.41 |
Quarterly Fundamentals Overview
Last date of statement is 2023-09-30 for Q3
Metric | History | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | -0.6 | 0 | 0 | 0 | |
Net income per share | -0.5 | -0.67 | -0.69 | -0.75 | -1.16 | |
Operating cash flow per share | -0.37 | -0.45 | -0.56 | -0.58 | -0.49 | |
Free cash flow per share | -0.48 | -0.61 | -0.61 | -0.61 | -0.52 | |
Cash per share | 6.79 | 6.19 | 5.4 | 4.78 | 4.26 | |
Book value per share | 7.63 | -5.72 | -6.27 | 5.57 | 4.53 | |
Tangible book value per share | 7.16 | 6.55 | 5.75 | 5.11 | 4.53 | |
Share holders equity per share | 7.63 | -5.72 | -6.27 | 5.57 | 4.53 | |
Interest debt per share | 0.52 | 0.51 | 0.55 | 0.53 | 0.51 | |
Market cap | 592.16M | 372.36M | 247.05M | 104.39M | 58.88M | |
Enterprise value | 331.2M | 135.73M | 38.91M | -78.43M | -102.58M | |
P/E ratio | -7.05 | -3.31 | -2.08 | -0.81 | -0.3 | |
Price to sales ratio | 0 | -14.9 | 0 | 0 | 0 | |
POCF ratio | -38.63 | -19.77 | -10.25 | -4.19 | -2.77 | |
PFCF ratio | -29.4 | -14.7 | -9.5 | -3.95 | -2.66 | |
P/B Ratio | 1.86 | -1.56 | -0.92 | 0.44 | 0.3 | |
PTB ratio | 1.86 | -1.56 | -0.92 | 0.44 | 0.3 | |
EV to sales | 0 | -5.43 | 0 | 0 | 0 | |
Enterprise value over EBITDA | -15.61 | -4.55 | -1.26 | 2.54 | 3.56 | |
EV to operating cash flow | -21.61 | -7.21 | -1.61 | 3.15 | 4.83 | |
EV to free cash flow | -16.45 | -5.36 | -1.5 | 2.97 | 4.63 | |
Earnings yield | -0.04 | -0.08 | -0.12 | -0.31 | -0.85 | |
Free cash flow yield | -0.03 | -0.07 | -0.11 | -0.25 | -0.38 | |
Debt to equity | 0.07 | -0.09 | -0.09 | 0.09 | 0.11 | |
Debt to assets | 0.06 | 0.06 | 0.08 | 0.08 | 0.09 | |
Net debt to EBITDA | 12.3 | 7.93 | 6.74 | 5.92 | 5.61 | |
Current ratio | 16.59 | 13.25 | 12.98 | 11.08 | 9.4 | |
Interest coverage | -1.28K | -1.21K | -1.75K | -8.72K | -52.26K | |
Income quality | 0.7 | 0.63 | 0.78 | 0.77 | 0.43 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | -0.26 | 0 | 0 | 0 | |
Research and developement to revenue | 0 | -1 | 0 | 0 | 0 | |
Intangibles to total assets | 0.05 | 0.06 | 0.06 | 0.07 | 0 | |
Capex to operating cash flow | 0.31 | 0.34 | 0.08 | 0.06 | 0.04 | |
Capex to revenue | 0 | 0.26 | 0 | 0 | 0 | |
Capex to depreciation | -6.34 | -6.13 | -1.53 | -1 | -0.55 | |
Stock based compensation to revenue | 0 | -0.17 | 0 | 0 | 0 | |
Graham number | 9.3 | 9.32 | 9.87 | 9.72 | 10.88 | |
ROIC | -0.06 | 0.15 | 0.14 | -0.12 | -0.22 | |
Return on tangible assets | -0.06 | -0.09 | -0.1 | -0.13 | -0.21 | |
Graham Net | 5.91 | 5.3 | 4.53 | 3.92 | 3.39 | |
Working capital | 268.52M | 241.33M | 216.71M | 189.82M | 166.12M | |
Tangible asset value | 298.2M | 272.88M | 246.75M | 219.6M | 194.68M | |
Net current asset value | 249.09M | 222.69M | 196.05M | 170.08M | 147.3M | |
Invested capital | 0.07 | -0.09 | -0.09 | 0.09 | 0.11 | |
Average receivables | 144K | 361.5K | 501K | 603K | 329.5K | |
Average payables | 4.36M | 4.49M | 3.58M | 2.93M | 3.59M | |
Average inventory | -129.5K | 1.15M | 2.33M | 2.08M | 2.15M | |
Days sales outstanding | 0 | -1.57 | 0 | 0 | 0 | |
Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 0 | -57.45 | 0 | 0 | 0 | |
Payables turnover | 0 | 0 | 0 | 0 | 0 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | -0.07 | 0.12 | 0.11 | -0.14 | -0.26 | |
Capex per share | -0.12 | -0.16 | -0.04 | -0.04 | -0.02 |
ACET Frequently Asked Questions
What is Adicet Bio, Inc. stock symbol ?
Adicet Bio, Inc. is a US stock , located in Boston of Ma and trading under the symbol ACET
Is Adicet Bio, Inc. buy or a sell ?
2 stock analysts have 2 predictions with a medium analyst target price of $32.5. The lowest prediction is $27 and the highest is $38
What is ACET stock prediction ?
What is Adicet Bio, Inc. stock quote today ?
Adicet Bio, Inc. stock price is $2.35 today.
Is Adicet Bio, Inc. stock public?
Yes, Adicet Bio, Inc. is a publicly traded company.